NO20004896L - Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav - Google Patents

Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav

Info

Publication number
NO20004896L
NO20004896L NO20004896A NO20004896A NO20004896L NO 20004896 L NO20004896 L NO 20004896L NO 20004896 A NO20004896 A NO 20004896A NO 20004896 A NO20004896 A NO 20004896A NO 20004896 L NO20004896 L NO 20004896L
Authority
NO
Norway
Prior art keywords
preparation
pyridazinone
hydrochloride compound
pyridazinone hydrochloride
carbonylmethoxy
Prior art date
Application number
NO20004896A
Other languages
English (en)
Other versions
NO20004896D0 (no
Inventor
Takashi Horiuchi
Sachiko Matsumoto
Hiroo Matsumoto
Minako Kamikawaji
Original Assignee
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd
Publication of NO20004896D0 publication Critical patent/NO20004896D0/no
Publication of NO20004896L publication Critical patent/NO20004896L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/12—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det er beskrevet et 3/2-hydroklorid av 4-klor-5-[3-(4-benzylpiperazin-1- yl)karbonylmetoksy-4-metoksybenzylamino]-3(2H)-pyridazinon, og også en fremgangsmåte for fremstilling av 3/2-hydrokloridet av 4-klor-5-[3-(4- benzylpiperazin-1-yl)karbonylmetoksy-4-metoksybenzylamino]-3(2H)- pyridazinon som omfatter krystallisering i alkoholtypeoppløsningsmiddel eller et alkoholtype-estertypeblandet oppløsningsmiddel l nærvær av hydrogen- klorid og vann.
NO20004896A 1998-03-31 2000-09-29 Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav NO20004896L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8592098 1998-03-31
PCT/JP1999/001629 WO1999050248A1 (en) 1998-03-31 1999-03-30 Pyridazinone hydrochloride compound and method for producing the same

Publications (2)

Publication Number Publication Date
NO20004896D0 NO20004896D0 (no) 2000-09-29
NO20004896L true NO20004896L (no) 2000-10-12

Family

ID=13872231

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004896A NO20004896L (no) 1998-03-31 2000-09-29 Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav

Country Status (14)

Country Link
US (1) US6310065B1 (no)
EP (1) EP1066265A1 (no)
JP (1) JP2002509919A (no)
KR (1) KR20010042078A (no)
CN (1) CN1293661A (no)
AU (1) AU742553B2 (no)
CA (1) CA2326506A1 (no)
IL (1) IL138521A0 (no)
NO (1) NO20004896L (no)
NZ (1) NZ506959A (no)
SK (1) SK14742000A3 (no)
TW (1) TW499425B (no)
WO (1) WO1999050248A1 (no)
ZA (1) ZA200004927B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US8978895B2 (en) * 2008-10-01 2015-03-17 Rickey E. Wark Self-cleaning coal separator grids with multiple cleaning combs
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3080131B2 (ja) * 1993-06-29 2000-08-21 日産化学工業株式会社 ピリダジノン誘導体
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
AU742553B2 (en) 2002-01-03
NZ506959A (en) 2002-02-01
TW499425B (en) 2002-08-21
WO1999050248A1 (en) 1999-10-07
US6310065B1 (en) 2001-10-30
ZA200004927B (en) 2001-12-24
KR20010042078A (ko) 2001-05-25
SK14742000A3 (sk) 2001-03-12
CN1293661A (zh) 2001-05-02
JP2002509919A (ja) 2002-04-02
AU2960699A (en) 1999-10-18
EP1066265A1 (en) 2001-01-10
NO20004896D0 (no) 2000-09-29
IL138521A0 (en) 2001-10-31
CA2326506A1 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
GR851039B (no)
TW347387B (en) Piperidine derivatives
DK417185D0 (da) 4,5-dihydro-3(2h)-pyridazinoner, fremgangsmaade til fremstilling derafog deres anvendelse
ES8400414A1 (es) "un procedimiento para preparar derivados de piridazinona".
UA7140A1 (uk) Спосіб отримання похідних піридіну
NO964813L (no) Fremgangsmåte for stabilisering av duocarmycinderivater
AU8722991A (en) Arylpyridazinones
DK0567271T3 (da) Steroidderivater til behandling af prostatahypertrofi, fremgangsmåde til fremstilling heraf og anvendelser heraf
ATE34741T1 (de) 6-(acylaminoaryl)-3(2h)-pyridazinonderivate, ihre herstellung und verwendung.
NZ313185A (en) 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
MY101042A (en) Pyridazinone derivatives,process for preparation thereof, and insecticidal compotions
MX9806211A (es) Composiciones herbicidas estables que contienen quelados metalicos de compuestos herbicidas de dionas.
NO932431L (no) Fremgangsmaate og mellomprodukter for fremstilling av azabicyklo(2,2,2)oktan-3-iminer
DK0998930T3 (da) Azasteroidforbindelser til behandling af alopecia, hirsutisme og seborrhea
ES8506002A1 (es) Procedimiento para la obtencion de 2-(1-indolinil-metil)-imidazolinas
JPS539321A (en) Agri-horticultural fungicide
BR9815967A (pt) Processo para a preparação de um derivado de amino-5-cloro de 3(2h)-piridazinona-4-substituìdo
DK0788472T3 (da) Fremgangsmåde til fremstilling af 5,6-dihydroxy-2-amino-1,2,3,4-tetrahydronaphthalenderivater
NO952913L (no) Forbedret fremgangsmåte og sammensetning for delignifisering av et lignocellulosemateriale
YU47353B (sh) Postupak za dobijanje aromatičnih etara
GR3006342T3 (no)
JPS54135785A (en) Pyridazinone derivative and its preparation
DK0963998T3 (da) Azasteroidforbindelse til behandling eller prævention af prostatacancer
Yamamoto Application of Sound Insulation Technique for Piano Lesson Room in Apartment House
EP1067119A4 (en) PROCESS FOR ISOLATION OF N-PROTECTED S-PHENYLCYSTEINE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application